Clinical Studies

The Memory & Aging Study by the Duke-UNC Alzheimer’s Disease Research Center aims to pinpoint the biological factors related to both regular brain aging and diseased brain decline.

The Registry is designed to increase awareness of Alzheimer’s disease and related dementias and to connect North Carolinians of all ages to research opportunities designed to improve brain health.

A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 (Lecanemab).

ALLFTD is a multisite observational research study aimed at understanding how frontotemporal lobar degeneration (FTD or FTLD) syndromes affect the brain.

A 12-Week Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Buntanetap in Participants with Mild-to-Moderate Alzheimer’s Disease (AD).

A Translational Study of ATH-1017 in Mild to Moderate Alzheimer’s Disease (ACT-AD), a randomized, double-blind, placebo-controlled, parallel-group 26-week trial evaluating ATH-1017 for the treatment of mild-to-moderate Alzheimer’s disease.

A 76-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer’s Disease Dementia.

By using an iPhone and Apple Watch, this study is evaluating how devices may be able to help measure thinking and memory changes in adults with mild cognitive impairment.

An oral medication, CT1812, is being investigated for the potential treatment of Dementia with Lewy Bodies (DLB). The purpose of this clinical trial is to learn about the safety of CT1812 and how well your body tolerates a once-a-day dose of CT1812.

DLBC is an observational research study aimed at learning more about Dementia with Lewy Bodies. The trial focuses on identifying biomarkers associated with the disease.

This clinical trial is an open label, dose-ranging study designed to evaluate gene therapy to treat patients who are APOE4 homozygotes with clinical diagnosis varying from mild cognitive impairment due to Alzheimer’s, mild dementia due to Alzheimer’s disease, and moderate dementia due to Alzheimer’s disease.

If you’re aged 65 and older, please volunteer for the PACT (Preventing Alzheimer’s with Cognitive Training) research study to see if computerized training exercises can reduce the risk of dementia.

This study is for people diagnosed with mild cognitive impairment. It tests the content and usability of the VRFACT, a performance-based measure of functional capacity.

Transposon Therapeutics, Inc. is investigating the safety and tolerability of TPN-101, an oral medication, in patients with Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) associated with a mutation in the C9orf72 gene.